SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines.

Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct of self-improvement.

The project “EVARCOV19: Development of a new drug based on Eravacycline for the treatment of SARS-COV-2” was co-funded by Fondo Europeo de Desarrollo Regional (FEDER), with the aim of promoting technological development, innovation and an investigation of quality.